Clinical Trials

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07332351 2026-03-13

TRIFECTA

Phase 1 Not yet recruiting

33 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07391670 2026-03-12

IMFINZI-subQ

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT07459634 2026-03-10

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

50 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07361497 2026-02-19

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07107750 2026-02-04

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Liver Neoplasms

NCT07247786 2025-12-30

MIGRANT

68 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

160 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07122089 2025-08-14

IOSPHERE

80 enrolled

Carcinoma, Hepatocellular

NCT07012798 2025-06-10

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

30 enrolled

Carcinoma, Hepatocellular

NCT06998719 2025-05-31

ACCESS

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06274879 2025-01-09

Ablatio

36 enrolled

Phase 3 Not yet recruiting

Bile Duct Neoplasms

NCT06719336 2024-12-05

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

182 enrolled

Small Cell Lung Carcinoma

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06650709 2024-10-23

NEOCATS

40 enrolled

Gynecologic

Ovarian Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT06530823 2024-07-31

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

38 enrolled

Phase 1 Not yet recruiting

Cholangiocarcinoma

NCT06304597 2024-03-12

PREDICT

18 enrolled

Phase 1/2 Not yet recruiting

Locally Advanced Rectal Carcinoma

NCT06111326 2023-11-01

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

83 enrolled

Carcinoma, Hepatocellular

NCT05484583 2022-08-05

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

58 enrolled

Phase 3 Not yet recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04465968 2020-07-10

DEEP_OCEAN

84 enrolled